Amgen/UCB’s Evenity gets EU Approval

Amgen/UCB’s new osteoporosis treatment Evenity (romosozumab), which increases bone formation and reduces bone loss, is the first to have been approved for use in Europe in almost a decade and can now be offered to postmenopausal women who suffer with severe osteoporosis who are at high risk of fracture.
The Royal Osteoporosis Society’s head of clinical operations, Alison Doyle, said: “Fragility fractures can often be avoided, but their prevention and management are being neglected despite a large personal, societal and economic impact. With the number of worldwide fractures expected to rise there is a growing need to take action and prioritize post-fracture care through better education, specialist services, lifestyles and medicines. Therefore, we welcome this approval as it represents a new, therapeutic option for both patients and health care professionals in addressing this neglected condition.”
Amgen’s executive vice president of Research and Development, David M. Reese, said: “Evenity is a significant step forward in the management of osteoporosis for physicians who need to treat patients with a medicine that can rapidly increase bone mineral density within 12 months.”